U
GRCE

UBS’s Grace Therapeutics GRCE Stock Holding History

UBS’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$15K Buy
41
+10
+32% +$4.7K ﹤0.01% 8380
2014
Q2 		$15K Buy
31
+26
+520% +$12.4K ﹤0.01% 8446
2014
Q1 		$3K Buy
+5
New +$3.05K ﹤0.01% 9879
2013
Q4 		– Sell
-5
Closed -$5K – 10827
2013
Q3 		$5K Buy
5
+4
+400% +$5.95K ﹤0.01% 9435
2013
Q2 		$1K Buy
+1
New +$1.2K ﹤0.01% 10048

Other funds holding GRCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
CP
Corbenic Partners Bethlehem, Pennsylvania $380M AUM 10.47% 1-Year Est. Return
EWM
Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return

UBS's GRCE Position: Q3 2014 in Review

UBS increased its Grace Therapeutics (GRCE) stake by 32% in Q3 2014, buying an estimated $4.7K and bringing the position to 41 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #8380.

UBS first reported a position in GRCE in Q2 2013 and has held it in 5 quarters since. 14 funds tracked by Wall St. Rank hold GRCE as of Q3 2014.

  • UBS held 41 shares of Grace Therapeutics worth $15K as of Q3 2014.
  • UBS bought 10 Grace Therapeutics shares in Q3 2014, an estimated $4.7K.
  • Grace Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8380 holding.
  • UBS first reported a position in Grace Therapeutics in Q2 2013 and has held it in 5 quarters since.
  • 14 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.